Bioequivalence Study of Two Fixed Dose Combination Tablet Formulations of Lopinavir and Ritonavir in Healthy Volunteers

Abstract

The study was designed to compare the rate and extent of absorption of two fixed dose combination tablet formulations of lopinavir (CAS 192725-17-0) and ritonavir (CAS 155213-67-5). This bioequivalence study was conducted using a standard preparation as reference and a generic alternative as test in 72 adult healthy volunteers within 18–45 years of age who received a single dose of the test or reference product under fasting conditions. A washout period of 10 d was maintained between period I and period II dosing. After dosing, blood samples were collected from 0 h (pre-dose) to 72 h post-dose administration. Lopinavir and ritonavir were quantified using a validated LC-MS/MS method. The data obtained for each subject was evaluated for primary pharmacokinetic variables C_max, AUC_0–72, and AUC_0–inf with respect to% ratio and 90% confidence interval for log-transformed data. The 90% confidence intervals (obtained by analysis of variance, ANOVA) were well within the bioequivalence acceptance range of 80% to 125%. Thus, it can be concluded that the evaluated formulations are bioequivalent in terms of rate and extent of absorption. The safety profiles of both the test and reference formulations were comparable.

Key words

AIDS - Antiretroviral drugs - CAS 155213-67-5 - CAS 192725-17-0 - Human immunodeficiency virus (HIV) - Lopinavir, bioequivalence, fixed dose combination with ritonavir - Ritonavir, bioequivalence, fixed dose combination with lopinavir

• References

• 1 Piacenti FJ. An update and review of antiretroviral therapy. Pharmacotherapy. 2006; Aug 26 (8) 1111-1133
• 2 von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today (Barc). 2007; Apr 43 (4) 221-247
• 3 King JR, Wynn H, Brundage R, Acosta EP. Pharmacokinetic enhancement of protease inhibitor therapy. Clin Pharmacokinet. 2004; 43 (5) 291-310
• 4 Hurst M, Faulds D. Lopinavir. Drugs. 2000; Dec 60 (6) 1371-1379 discussion 1380–1381
• 5 Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003; 63 (8) 769-802
• 6 Klein CE, Chiu YL, Awni W, Zhu T, Heuser RS, Doan T et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007; Apr 1 44 (4) 401-410
• 7 la Porte CJL et al. Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers. Antimicrob Agents Chemother. May 2004; p Vol 48 No (5) 1553-1560
• 8 Tan D, Walmsley S. Lopinavir plus ritonavir: a novel protease inhibitor combination for HIV infections. Expert Rev Anti Infect Ther. 2007; Feb 5 (l) 13-28
• 9 Qazi NA, Morlese JF, Pozniak AL. Lopinavir/ritonavir (ABT-378/r). Expert Opin Pharmacother. 2002; Mar 3 (3) 315-327
• 10 Kaplan SS, Hicks CB. Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert Opin Pharmacother. 2005; Aug 6 (9) 1573-1585
• 11 Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006; 66 (9) 1275-99